Citations

Clear

7552 citation(s) found for "Ho, Matthew".

Abstract A133: APOBEC3 confers resistance to oncolytic VSV therapy
Wongthida, Phonphimon , Kottke, Timothy, Thompson, Jill, Schuelke, Matthew , Molan, Amy, Pulido, José S. , Selby, Peter J. , Vile, Richard G. , Huff, Amanda L. , Driscoll, Christopher B. , Shim, Kevin G. , Harris, Reuben S. , Harrington, Kevin J. , Melcher, Alan , Evgin, Laura

Mayo Clinic

Cancer Immunology Research | February 4, 2019 | Volume: 7 | Issue: 2_Supplement | Pages: A133-A133

10.1158/2326-6074.cricimteatiaacr18-a133 Get It

Abstract Tumor cells are able to evade cytotoxic therapies through the accumulation of genomic mutations and rapid evolution. In the case of oncolytic virotherapy, understanding the mechanisms by which cancer cells develop resistance to infection and lysis is critical to the development of more effective viral-based platforms. Here, we identify APOBEC3 as an important factor involved in the restriction of vesicular stomatitis virus (VSV). We show that VSV infection of B16 murine melanoma cells upregulated APOBEC3 in an IFNβ-dependent manner, which was responsible for the evolution of virus-resistanT-cell populations and suggested that APOBEC3 expression promoted the acquisition of a virus-resistant phenotype. ShRNA knockdown of APOBEC3 in B16 cells diminished their capacity to develop resistance to VSV infection in vitro, and enhanced the therapeutic effect of VSV in vivo. Similarly, overexpression of human APOBEC3B promoted the acquisition of resistance to oncolytic VSV in murine melanoma and glioblastoma lines, as well as in a human melanoma cell line in vitro and in vivo. Finally, we demonstrate that progeny virus obtained after passage through APOBEC3B overexpressing cells contained more defective interfering particles, thereby indicating that APOBEC3B directly affected the fitness of VSV, an RNA virus that has not previously been identified to be restricted by APOBEC3B. This research identifies APOBEC3 enzymes as key players to target in order to improve the efficacy of oncolytic viruses as well as broader nucleic acid-based therapeutic platforms. Citation Format: Amanda L. Huff, Phonphimon Wongthida, Timothy Kottke, Jill Thompson, Christopher B. Driscoll, Matthew Schuelke, Kevin G. Shim, Reuben S. Harris, Amy Molan, Jose S. Pulido, Peter J. Selby, Kevin J. Harrington, Alan Melcher, Laura Evgin, Richard Vile. APOBEC3 confers resistance to oncolytic VSV therapy [abstract]. In: Proceedings of the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; Sept 30-Oct 3, 2018; New York, NY. Philadelphia (PA): AACR; Cancer Immunol Res 2019;7(2 Suppl):Abstract nr A133.
Chronic Pancreatitis
Schwarzenberg, Sarah Jane , Uç, Aliye , Zimmerman, Bridget, Wilschanski, Michael , Wilcox, C. Mel , Werlin, Steven L. , Troendle, David M. , Tang, Gong , Slivka, Adam, Sherman, Stuart , Shah, Uzma , Sandhu, Bimaljit S., Romagnuolo, Joseph , Rhee, Sue, Pohl, John F. , Perito, Emily R. , Ooi, Chee Y. , Nathan, Jaimie D. , Muniraj, Thiruvengadam , Morinville, Véronique D., McFerron, Brian A. , Mascarenhas, Maria R., Maqbool, Asim , Liu, Quin , Lin, Tom K. , Lewis, Michele D. , Husain, Sohail Z. , Heyman, Melvin B. , Guda, Nalini M. , Gonska, Tanja , Giefer, Matthew J. , Gelrud, Andrés , Gariepy, Cheryl E. , Gardner, Timothy B. , Freedman, Steven D., Forsmark, Christopher E., Fishman, Douglas S., Coté, Gregory A. , Conwell, Darwin L. , Barth, Bradley, Banks, Peter A. , Anderson, Michelle A. , Amann, Stephen T. , Alkaade, Samer, Abu‐El‐Haija, Maisam , Abberbock, Judah , Lowe, Mark E. , Yadav, Dhiraj , Lewis, Michele, Lewis, Michele D , Whitcomb, David C. , Singh, Vikesh K. , Himes, Ryan , Brand, Randall E. , Bellin, Melena D.

Mayo Clinic

Journal of Pediatric Gastroenterology and Nutrition | February 2, 2019 | Volume: 68 | Issue: 4 | Pages: 566-573

10.1097/mpg.0000000000002279 | PMID 30897605 Get It

ABSTRACTObjectives:The aim of the present study was to investigate the natural history of chronic pancreatitis (CP); patients in the North American Pancreatitis Study2 (NAPS2, adults) and INternational Study group of Pediatric Pancreatitis: In search for a cuRE (INSPPIRE, pediatric) were compared.Methods:Demographics, risk factors, disease duration, management and outcomes of 224 children and 1063 adults were compared using appropriate statistical tests for categorical and continuous variables.Results:Alcohol was a risk in 53% of adults and 1% of children (P < 0.0001); tobacco in 50% of adults and 7% of children (P < 0.0001). Obstructive factors were more common in children (29% vs 19% in adults, P = 0.001). Genetic risk factors were found more often in children. Exocrine pancreatic insufficiency was similar (children 26% vs adult 33%, P = 0.107). Diabetes was more common in adults than children (36% vs 4% respectively, P < 0.0001). Median emergency room visits, hospitalizations, and missed days of work/school were similar across the cohorts. As a secondary analysis, NAPS2 subjects with childhood onset (NAPS2‐CO) were compared with INSPPIRE subjects. These 2 cohorts were more similar than the total INSPPIRE and NAPS2 cohorts, including for genetic risk factors. The only risk factor significantly more common in the NAPS2‐CO cohort compared with the INSPPIRE cohort was alcohol (9% NAPS2‐CO vs 1% INSPPIRE cohorts, P = 0.011).Conclusions:Despite disparity in age of onset, children and adults with CP exhibit similarity in demographics, CP treatment, and pain. Differences between groups in radiographic findings and diabetes prevalence may be related to differences in risk factors associated with disease and length of time of CP.
Association of Intravitreal Anti–Vascular Endothelial Growth Factor Therapy With Risk of Stroke, Myocardial Infarction, and Death in Patients With Exudative Age-Related Macular Degeneration
Starr, Matthew R. , AbouChehade, Jackson E., Damento, Gena M., García, María Dolores Aguilar , Shah, Saumya M. , Hodge, David O. , Meissner, Irene, Bakri, Sophie J. , Iezzi, Raymond , García, María, Starr, Matthew R , Dalvin, Lauren A. , Garcia, Maria

Mayo Clinic

JAMA Ophthalmology | January 31, 2019 | Volume: 137 | Issue: 5 | Pages: 483

10.1001/jamaophthalmol.2018.6891 | PMID 30703203 Get It

Bacterial Cultures at the Time of Artificial Urinary Sphincter Revision Surgery in Clinically Uninfected Devices: A Contemporary Series
Ziegelmann, Matthew , Linder, Brian J. , Avant, Ross, Elliott, Daniel S. , Ziegelmann, Matthew J, Avant, Ross A, Linder, Brian J

Mayo Clinic

Journal of Urology | January 31, 2019 | Volume: 201 | Issue: 6 | Pages: 1152-1157

10.1097/ju.0000000000000102 | PMID 30707131 Get It

Lumbar fusion involving the sacrum increases dislocation risk in primary total hip arthroplasty
Salib, Christopher G. , Reina, Nicolas , Perry, Kevin I. , Taunton, Michael J. , Berry, Daniel J. , Taunton, Michael J , Berry, Daniel J , Abdel, Matthew P.

Mayo Clinic

The Bone & Joint Journal | January 31, 2019 | Volume: 101-B | Issue: 2 | Pages: 198-206

10.1302/0301-620x.101b2.bjj-2018-0754.r1 | PMID 30700125 Get It

Aims Concurrent hip and spine pathologies can alter the biomechanics of spinopelvic mobility in primary total hip arthroplasty (THA). This study examines how differences in pelvic orientation of patients with spine fusions can increase the risk of dislocation risk after THA. Patients and Methods We identified 84 patients (97 THAs) between 1998 and 2015 who had undergone spinal fusion prior to primary THA. Patients were stratified into three groups depending on the length of lumbar fusion and whether or not the sacrum was involved. Mean age was 71 years (40 to 87) and 54 patients (56%) were female. The mean body mass index (BMI) was 30 kg/m2 (19 to 45). Mean follow-up was six years (2 to 17). Patients were 1:2 matched to patients with primary THAs without spine fusion. Hazard ratios (HR) were calculated. Results Dislocation in the fusion group was 5.2% at one year versus 1.7% in controls but this did not reach statistical significance (HR 1.9; p = 0.33). Compared with controls, there was no significant difference in rate of dislocation in patients without a sacral fusion. When the sacrum was involved, the rate of dislocation was significantly higher than in controls (HR 4.5; p = 0.03), with a trend to more dislocations in longer lumbosacral fusions. Patient demographics and surgical characteristics of THA (i.e. surgical approach and femoral head diameter) did not significantly impact risk of dislocation (p > 0.05). Significant radiological differences were measured in mean anterior pelvic tilt between the one-level lumbar fusion group (22°), the multiple-level fusion group (27°), and the sacral fusion group (32°; p < 0.01). Ten-year survival was 93% in the fusion group and 95% in controls (HR 1.2; p = 0.8). Conclusion Lumbosacral spinal fusions prior to THA increase the risk of dislocation within the first six months. Fusions involving the sacrum with multiple levels of lumbar involvement notably increased the risk of postoperative dislocation compared with a control group and other lumbar fusions. Surgeons should take care with component positioning and may consider higher stability implants in this high-risk cohort.
Abstract TMP96: Carotid Plaque Characteristics Correlated to Baseline Vascular Risk Factors in a Large Randomized Trial: Results from CREST-2
Lal, Brajesh K. , Chrencik, Matthew T. , Khan, Amir , Jones, Michael , Sternbergh, Charles, Rapp, Joseph H., Mukherjee, Dipankar , Henke, Peter K. , Yokemick, John, Moore, Wesley S. , Voeks, Jenifer H. , Brott, Thomas G. , Huston, John , Sikdar, Siddhartha , Howard, George , Meschia, James F.

Mayo Clinic

Stroke | January 30, 2019 | Volume: 50 | Issue: Suppl_1 | Pages: No page available

10.1161/str.50.suppl_1.tmp96 Get It

Objectives: Assessment of carotid disease is most commonly performed with duplex ultrasonography (DUS). Measures of plaque area and tissue composition from DUS images may identify patients at risk for future neurologic events, and may assess the effects of vascular risk-factor modification (by measuring change in plaque area and/or tissue constituents). We quantified plaque area and tissue constituents from DUS images of CREST-2 participants at baseline and correlated them with their baseline vascular risk factors. Methods: CREST-2 consists of two multicenter, randomized trials in patients with asymptomatic ≥70% carotid stenosis comparing intensive medical management (IMM) plus endarterectomy or stenting vs IMM alone. Baseline B-mode DUS images from 500 patients underwent manual plaque outlining and automatic pixel brightness assessment. Plaque area, grayscale median (GSM), Gray-Weale score for heterogeneity, and areas for intraplaque hemorrhage and lipid were the output parameters. We computed the parameter estimates (95% confidence intervals) for baseline patient characteristics (age, sex, race, diabetes, smoking, BMI, blood pressure and LDL levels) versus plaque characteristics. Results: High-risk plaque features (larger plaque area, lower GSM , lower Gray-Weale scores, or larger areas of hemorrhage and lipid) were present in older patients, males, and those with elevated diastolic blood pressure and LDL levels (Table). Conclusions: In a randomized trial of asymptomatic patients with high-grade carotid stenosis, DUS-based computation of plaque geometry and tissue composition is feasible. Elevated diastolic blood pressure and LDL levels at baseline are associated with high-risk plaque characteristics. These novel findings identify potentially modifiable targets for aggressive treatment to reduce stroke-risk in patients with carotid stenosis.
Abstract 17: Apolipoprotein E and Intracerebral Hemorrhage: A Trans-Ethnic Meta-Analysis
Morotti, Andrea , Moomaw, Charles J. , Flaherty, Matthew L. , Jiménez-Conde, Jordi , Słowik, Agnieszka , Pichler, Alexander , Tirschwell, David L, Brown, Devin L. , Silliman, Scott, Worrall, Bradford B. , Kidwell, Chelsea S., Kittner, Steven J. , Sudlow, Catherine L, Viswanathan, Anand , Greenberg, Steven M. , Falcone, Guido J. , Langefeld, Carl D. , Woo, Daniel , Marini, Sandro , Pezzini, Alessandro , Montaner, Joan , Cuadrado‐Godia, Elisa , Tirschwell, David L, Selim, Magdy H. , Meschia, James F. , Testai, Fernando D. , Deary, Ian J. , Salman, Rustam Al‐Shahi , Sudlow, Catherine L, Klijn, Catharina J.M. , Fernández‐Cadenas, Israel , Lindgren, Arne G. , Goldstein, Joshua Norkin , Rosand, Jonathan M. , Anderson, Christopher D.

Mayo Clinic

Stroke | January 30, 2019 | Volume: 50 | Issue: Suppl_1 | Pages: No page available

10.1161/str.50.suppl_1.17 Get It

Introduction: Risk of lobar and non-lobar intracerebral hemorrhage (ICH) varies among blacks, whites and Hispanics. We sought to determine whether these differences could be due to variability in the effects of Apolipoprotein E (APOE) epsilon (ε) alleles, the most potent genetic risk factor for ICH. Methods: Primary ICH cases and controls were collected from US and European sites contributing to the International Stroke Genetic Consortium (ISGC). We meta-analyzed the effects of APOE allele status on ICH risk applying a two-stage clustering approach based on race/ethnicity and the contributing study. Models were adjusted for age, sex, history of hypertension, hypercholesterolemia, warfarin, statin and antiplatelet use, smoking and alcohol use. A propensity score analysis was used to model the influence of APOE against the burden of hypertension across races/ethnicities. Results: 13,124 subjects (54.5% male, median age 66 years) were included. In whites, APOE ε2 (odds ratio (OR)=1.85, 95% confidence interval (CI)=1.27-2.69, p<0.001) and APOE ε4 (OR=1.94, 95% CI=1.58-2.38, p<0.001) were independently associated with lobar ICH risk, however within self-identified Hispanics and blacks, no associations were found (Figure). After propensity score-matching for hypertension burden, APOE ε4 was associated with lobar ICH risk among whites (OR=1.12, 95% CI=1.08-1.17) and Hispanics (OR=1.07, 95% CI=1.01-1.15, p=0.01), but not blacks (OR=1.02 95% CI=0.98-1.07, p=0.251). APOE ε2 and ε4 did not show an effect on non-lobar ICH risk in any race/ethnicity. Conclusion: APOE ε4 and ε2 alleles affect lobar ICH risk variably by race and ethnicity. Associations are confirmed in whites but can be shown in Hispanics only when the excess burden of hypertension is propensity score-matched. Further studies are needed to explore interactions between APOE alleles and environmental exposures that vary by race and ethnicity in representative populations at risk for ICH.
TBX3 promotes progression of pre‐invasive breast cancer cells by inducing EMT and directly up‐regulating SLUG
Krstic, Milica , Kolendowski, Bart , Cecchini, Matthew J. , Postenka, Carl O., Hassan, Haider M., Andrews, Joseph, MacMillan, Connor D., Williams, Karla C. , Torchia, Joseph , Tuck, Alan B., Leong, Hon S. , Brackstone, Muriel , Chambers, Ann F.

Mayo Clinic

The Journal of Pathology | January 30, 2019 | Volume: 248 | Issue: 2 | Pages: 191-203

10.1002/path.5245 | PMID 30697731 Get It

AbstractThe acquisition of cellular invasiveness by breast epithelial cells and subsequent transition from ductal carcinoma in situ (DCIS) to invasive breast cancer is a critical step in breast cancer progression. Little is known about the molecular dynamics governing this transition. We have previously shown that overexpression of the transcriptional regulator TBX3 in DCIS‐like cells increases survival, growth, and invasiveness. To explore this mechanism further and assess direct transcriptional targets of TBX3 in a high‐resolution, isoform‐specific context, we conducted genome‐wide chromatin‐immunoprecipitation (ChIP) arrays coupled with transcriptomic analysis. We show that TBX3 regulates several epithelial–mesenchymal transition (EMT)‐related genes, including SLUG and TWIST1. Importantly, we demonstrate that TBX3 is a direct regulator of SLUG expression, and SLUG expression is required for TBX3‐induced migration and invasion. Assessing TBX3 by immunohistochemistry in early‐stage (stage 0 and stage I) breast cancers revealed high expression in low‐grade lesions. Within a second independent early‐stage non‐high‐grade cohort, we observed an association between TBX3 level in the DCIS and size of the invasive focus. Additionally, there was a positive correlation between TBX3 and SLUG, and TBX3 and TWIST1 in the invasive carcinoma. Pathway analysis revealed altered expression of several proteases and their inhibitors, consistent with the ability to degrade basement membrane in vivo. These findings strongly suggest the involvement of TBX3 in the promotion of invasiveness and progression of early‐stage pre‐invasive breast cancer to invasive carcinoma through the low‐grade molecular pathway. © 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
Mortality and glycemic control among patients with gastric and esophageal cancer and diabetes mellitus.
Karlin, Nina J. , Verona, Patricia M , Buras, Matthew , Kosiorek, Heidi , Cook, Curtiss B.

Mayo Clinic

Journal of Clinical Oncology | January 29, 2019 | Volume: 37 | Issue: 4_suppl | Pages: 73-73

10.1200/jco.2019.37.4_suppl.73 Get It

73 Background: This study evaluated the impact of diabetes mellitus (DM) on survival in gastric and esophageal cancer patients, and examined the impact of these cancers on glycemic control in DM. Methods: Patients with newly diagnosed gastric and esophageal cancers with DM (n = 92) were identified from the Institutional Cancer Registry and matched to 92 gastric and esophageal cancer patients without DM according to age, gender and year of cancer diagnosis (2006 to 2016). The electronic medical record provided information on DM and cancer therapies and laboratory results. Overall survival (OS) was estimated with the Kaplan-Meier method and compared by Cox regression analysis using stratification for matched pairs. Mixed models were used to compare hemoglobin A1c (HbA1c) and glucose during the year following cancer diagnosis. Results: Mean age of the entire cohort was 68 years, 91% were white, 78% were men, and 53% had stage III/IV disease. Adenocarcinoma (79%) was the most common histologic type. BMI was significantly different between DM and non-DM patients (p = 0.006). Alcohol use at time of cancer diagnosis was more prevalent in non-DM patients vs. DM (p = 0.018). Among those with DM, mean HbA1c during the year following cancer diagnosis was 6.8%. Mean glucose was significantly different between DM and non-DM patients (149 mg/dL vs. 116 mg/dL, p < 0.001). For glucose, there was a significant interaction effect (p = 0.005) as DM patients demonstrated a decrease in glucose values over time compared to non-DM patients. Median follow-up time was 35 months. Three year OS was estimated at 46% (95% CI: 36-58%) for DM patients versus 52.0% (95% CI: 41-64%) in non-DM (p = 0.25). Hazard ratio (stratification for matched pairs) was 1.95 (95% CI: 1.14 – 3.43; p = 0.02). Three year PFS was estimated at 40% (95% CI: 31-53%) for DM patients versus 50% (95% CI: 40-63%) for non-DM patients (p = 0.12). Hazard ratio (stratification for matched pairs) was 1.74 (95% CI: 1.04-2.90; p = 0.03). Conclusions: Gastric and esophageal cancer and its treatment did not affect glycemic control. Risks of death and progression are greater in DM patients as compared to non-DM.
Proceedings from the Ice Hockey Summit III: Action on Concussion
Smith, Aynsley M., Alford, Patrick A., Aubry, Mark, Benson, Brian W., Black, Amanda M. , Brooks, Alison, Burke, Charles J., Eaves, Michael, Eickhoff, Chad, Erredge, Kristen, Farrell, Kyle , Finnoff, Jonathon, Giza, Christopher C. , Greenwald, Richard M., Hoshizaki, Blaine, Huston, John , Jorgensen, Janelle, Leaf, Matthew, Leddy, John J. , Margarucci, Kevin, Munce, Thayne A. , Prideaux, Cara C. , Roberts, William O. , Shen, Francis X. , Soma, David , Tabrum, Mark, Stuart, Michael, Wethe, Jennifer V. , Whitehead, James R., Wiese‐Bjornstal, Diane M. , Dodick, David, Joyner, Michael, Krause, David, Prideaux, Cara, Stuart, Michael B, Wethe, Jennifer, Farrell, Kyle J , Alford, Patrick W. , D’Arcy, Ryan C.N. , Dodick, David W. , Fraser, Douglas D. , Joyner, Michael J. , Krause, David A. , LaVoi, Nicole M. , Margulies, Susan Sheps , Mihalik, Jason P. , Oeur, Anna , Stuart, Michael J. , Wethe, Jennifer V

Mayo Clinic

Current Sports Medicine Reports | January 29, 2019 | Volume: 18 | Issue: 1 | Pages: 23-34

10.1249/jsr.0000000000000557 | PMID 30624332 Get It

The Ice Hockey Summit III provided updated scientific evidence on concussions in hockey to inform these five objectives: 1) describe sport-related concussion (SRC) epidemiology, 2) classify prevention strategies, 3) define objective, diagnostic tests, 4) identify treatment, and 5) integrate science and clinical care into prioritized action plans and policy. Our action plan evolved from 40 scientific presentations. The 155 attendees (physicians, athletic trainers, physical therapists, nurses, neuropsychologists, scientists, engineers, coaches, and officials) voted to prioritize these action items in the final Summit session. 1) Establish a national and international hockey data base for SRC at all levels, 2) eliminate body checking in Bantam youth hockey games, 3) expand a behavior modification program (Fair Play) to all youth hockey levels, 4) enforce game ejection penalties for fighting in Junior A and professional hockey leagues, 5) establish objective tests to diagnose concussion at point of care (POC), and 6) mandate baseline testing to improve concussion diagnosis for all age groups. Expedient implementation of the Summit III prioritized action items is necessary to reduce the risk, severity, and consequences of concussion in the sport of ice hockey.